An analytical study of annual bleeding rates in haemophilia patients receiving low dose factor prophylaxis and those receiving episodic factor doses

Mrunal Pathradkar; Varun Bafna; Anita Paritekar

doi:10.18203/2320-6012.ijrms20241546

Authors

Mrunal Pathradkar Department of Medicine, RCSM GMC, Kolhapur, Maharashtra, India
Varun Bafna Department of Medicine, RCSM GMC, Kolhapur, Maharashtra, India
Anita Paritekar Department of Medicine, RCSM GMC, Kolhapur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241546

Keywords:

Annual bleeding rate, Factor replacement therapy, People with haemophilia, Prophylactic factor doses

Abstract

Background: This study aimed to assess the impact of low dose factor prophylaxis on haemophilia patients with respect to annual bleeding rates and severity of bleeding events.

Methods: This is an analytical study. All patients of HAEMOPHILIA A AND B who are registered with CPRH haemophilia treatment centre from January 2022 to December 2022 were included and were followed up every month from January 2022. The study population was divided into two groups: those receiving regular low dose factor prophylaxis and those receiving episodic factor treatment. Both the group participants were matched for severity of factor deficiency and age. The collected data was compared with respect to the annual bleeding rate as well as severity of bleeding episodes in the two defined groups.

Results: There were 100 study patients, and 16 of them are receiving regular low dose factor prophylaxis. The average bleeding episodes were found to be more in patients receiving episodic factor doses (ABR in moderate haemophilia= 3.511+/-0.81, ABR in severe haemophilia=5.38+/-4, 53) as compared to those receiving prophylactic factor doses (ABR in moderate haemophilia = 0.16+/-0.32, ABR in severe haemophilia=0.3+/-0.29). The incidence of severe bleeds (those requiring hospitalisation) was higher in patients receiving episodic factor therapy (15) as compared to those receiving regular low dose factor prophylaxis (1).

Conclusions: Haemophilia patients receiving episodic factor doses have higher Annual Bleeding Rate as compared to patients receiving regular low dose factor prophylaxis. Also, patients receiving prophylaxis face less severe forms of bleeding episodes as compared to other group of patients.

Metrics

Metrics Loading ...

References

Srivastava A, Tariq M, Heijnen L. Haemophilia in developing countries-the challenge of detection and diagnosis. In: Comprehensive Haemophilia Care in Developing Countries. Chapter 2. Lahore: Feroz Sons (Pvt) Ltd.; 2012:17-25.

Kar A, Phadnis S, Dharmarajan S, Nakade J. Epidemiology & social costs of haemophilia in India. Ind J Medi Res. 2014;140(1):19-31.

World Federation of Hemophilia (WFH). Report on the Annual Global Survey 2011, 2013. Available at: http://www1.wfh.org/publications/files/pdf-1488.pdf. Accessed on 9 May, 2013.

Nigam RK, Choudhary R, Malik R, Kothari S, Verma KP, Shrivastava A, et al. Clinicohematological study of hemophilia patients in Bhopal. J Evolut Medi Dent Sci. 2014;3(11):2910-6.

Gringeri A. Prospective controlled studies on prophy laxis: an Italian approach. Haemophilia. 2003;9(Suppl. 1):38-42.

Uddin MM, Rahman MJ, Rahman MM, Sultana SA, Shah MS. Clinico-pathological study on haemophilia: An analysis of 50 cases. J Bangl Coll Phys Surge. 2006;24(2):50.

Karim MA, Siddique R, Jamalcy, Islam A. Clinical profile of haemophilia in children in A Tertiary care hospital. Bangl J Child Heal. 2013;37(2):90-6.

Hazewinkel MH, Hoogerwerf JJ, Hesseling PB, Hartley P, MacLean PE, Peters M, et al. Haemophilia patients aged 0-18 years in the Western Cape. South Afr Med J. 2003;93(10):793-6.

Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR, et al. Prophylaxis in haemophilia: a double‐blind controlled trial. Brit J Haematol. 1976;33(1):81-90.

Larsson SA. Hemophilia in Sweden. Studies on demography of hemophilia and surgery in hemophilia and von Willebrand’s disease. Acta Med Scand Suppl. 1984; 684:1-72.

Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thrombos Haemost. 2006;4(6):1228-36.

Manco-Johnson MJ, Blanchette VS. North American prophylaxis studies for persons with severe haemophilia: background, rationale and design. Haemophilia. 2003;9(Suppl. 1):44-8.